Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800176 · ClinicalTrials.gov registry record · Phase 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 394
- Enrollment target
NCT00800176: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00800176 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 394 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (196% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00800176, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 394 participants
- Enrollment target
Study Summary
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Patients will be randomized to one of 6 groups to receive RO4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. Patients pre-treated with stable metformin will continue to take their usual dose of metformin throughout the study.The anticipated time on study treatment is \<=3 months
Interventions
- DRUG Placebo
- DRUG RO4998452
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2009-01-22 |
| Est. Completion | 2009-10-28 |
| Phase | Phase 2 |
What the finished NCT00800176 record still lists
NCT00800176 is an interventional study that assigns participants to a tested intervention. The registered 394 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (196% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00800176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00800176 about?
NCT00800176 is a clinical study titled "A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus". This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Patients will be randomized to one of 6 groups to receive RO4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. P...
What is the current status of trial NCT00800176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 394 participants. The study started on 2009-01-22. Estimated completion is 2009-10-28.
What interventions are being tested in trial NCT00800176?
The interventions under investigation include: Placebo (DRUG), RO4998452 (DRUG).
Who is sponsoring clinical trial NCT00800176?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00800176's enrollment target sits among peer trials
394 103rd of 2000 higher than 1,897 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI